Drug discovery biology

Drug discovery biology

The Drug Discovery Biology research teams within the Monash Institute of Pharmaceutical Sciences have broad expertise in receptor molecular and cellular biology, whole-animal studies and translational discovery research.

DDB laboratories

Research in the Drug Discovery Biology Theme is conducted by independently-funded groups that share core facilities and infrastructure. We are supported by government grant schemes and key industry partnerships, and collaborate extensively with national and international researchers.

Therapeutic foci

Front lawn of Monash Parkville campus

Our doctoral program

The Drug Discovery Biology doctoral PhD offers an elite program in a world class scientific environment to ensure our graduates are not only specialists in their chosen scientific field, but also have an understanding of diverse topics, techniques and practices relevant to drug discovery.

Find out more

Drug discovery biology PhD student

Research Capabilities

Our research is underpinned by a broad range of experimental approaches.

Researchers

A-Z list of all research staff

DDB news

Watch

Explore our videos to learn more about our research and postgraduate opportunities.

Latest news from MIPS


Contact us

Email: pharm-ddb-enquiries@monash.edu

Telephone: +61 3 9903 9614

.

For prospective postgraduate students

See the latest news

Leading Australian metabolic disease researcher wins Society of Endocrinology International Medal

Prominent metabolic disease researcher Professor Mark Febbraio, from the Monash Institute of Pharmaceutical Sciences (MIPS), has been awarded the 2021 International Medal from the UK’s Society of Endocrinology.

Breakthrough discovery paves the way for preventing sugar-induced liver disease

A team of international researchers including Monash University academics has discovered that, contrary to previous belief, fructose causes liver toxicity by changing the barrier function of the intestine.

New international collaboration showcases drug development potential

New research from Monash Institute of Pharmaceutical Sciences (MIPS), in collaboration with the Max Planck Institute, Mayo Clinic, University of Auckland, University of Essex and University of Tokyo, has uncovered new structures of protein

MIPS and Thermo Fisher announce ‘GPCR Cryo-EM and Drug Design’ collaboration

A new collaboration between MIPS researcher Professor Patrick Sexton’s team and the leading biological cryo-EM biotechnology product development company, Thermo Fisher Scientific, will bring cryo-electron microscopy of G protein-coupled
Paulina Garcia Ramirez and Nicholas Veldhuis

Weaning ourselves off opioids: Monash researchers use nanotechnology for pain relief

Researchers at the Monash Institute of Pharmaceutical Sciences (MIPS) and the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology (CBNS) have created a nanoparticle that could improve the properties of painkillers by delivering

Professor Rebecca Ritchie to head DDB

Leading cardiovascular disease researcher Professor Rebecca Ritchie has been appointed as the new Theme Leader of the Drug Discovery Biology Theme in the Monash Institute of Pharmaceutical Sciences (MIPS).

MIPS maintains top score in 2018 ERA rankings

The Monash Institute of Pharmaceutical Sciences has again received excellent results in the latest Excellence in Research for Australia (ERA) rankings.
Representatives of the three PharmAlliance partners: (L-R) Dr Andreia Bruno (Monash), Dr Oksana Pyzik (UCL) and Dr David Steeb (UNC)

PharmAlliance meets at Monash University

PharmAlliance, the research, professional practice and education partnership between the Schools of Pharmacy at Monash University, University College London (UCL) and the University of North Carolina at Chapel Hill (UNC), has held its

Faculty success in major Commonwealth grant programs

The Monash Faculty of Pharmacy and Pharmaceutical Sciences has been awarded nearly $20 million dollars in research funding in the recent rounds of grants announced by the National Health and Medical Research Council (“NHMRC”) and the